FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)

View source ↗

Summary

The FDA approved a supplemental application for JUXTAPID (lomitapide mesylate) submitted by Amryt Pharmaceuticals DAC, resulting in a labeling update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• JUXTAPID (lomitapide)

Snippet

SUPPL AP for JUXTAPID (LOMITAPIDE MESYLATE)